腫瘤CTC和ctDNA介紹

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy,

Catherine Alix-Panabières,Cancer Discov;6(5); 479–91. ©2016 AACR Published OnlineFirst March 11, 2016; DOI: 10.1158/2159-8290.CD-15-1483.

原發(fā)腫瘤（乳房、結腸、肺、前列腺癌）在形成生長早期，會釋放細胞進入血液循環(huán)。通過各種技術可以富集檢測這些循環(huán)腫瘤細胞的物理和生物性質。

循環(huán)腫瘤細胞，Circulating Tumor cell，簡稱CTC。CTC釋放點：原發(fā)腫瘤和轉移腫瘤。

CTC死亡后還會釋放出循環(huán)腫瘤DNA，Circulating Tumor DNA，簡稱ctDNA。

CTCs和ctDNA的分析是液體活檢診斷的基石。

CTC和ctDNA的臨床應用

腫瘤檢測：CTCs和ctDNA應用腫瘤的早期檢測很受關注，面臨的挑戰(zhàn)是目前分析的特定性和敏感度。

預后評估：多種腫瘤已經實現(xiàn)預后評估，尤其是乳癌。

指導系統(tǒng)治療：

病人亞群分類（stratification）。

CTC研究進展

CTC研究是很活躍的領域，截止2015年12月發(fā)表在PubMed的文獻有17000篇。隨著循環(huán)游離腫瘤DNA分析的發(fā)展，zui近才開始使用“液體活檢”這個條目。分子水平的靈敏分析方便研究者從血漿中篩選特定腫瘤突變的ctDNA，因此ctDNA和CTC成為富有競爭力的生物標志物。不過建議把ctDNA和CTC作為兩種互補的信息資源，根據(jù)應用區(qū)分。文章簡單討論生物和檢測技術，重點是ctDNA和CTC的腫瘤臨床應用。

血漿游離循環(huán)腫瘤DNA（ctDNA）保存管

——Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管內含特殊保護劑，可以保護血漿循環(huán)游離DNA（包括游離循環(huán)腫瘤DNA），常溫下可以保存CTC達14天。

英文名稱：Streck Cell-Free DNA BCT® BLOOD COLLECTION TUBE

中文名稱：Streck BCT® 血漿游離DNA采血/保存管

貨號：218962,230253

Streck 血漿游離DNA采血管是一種直接提取的全血收集管，用于收集、運輸和儲存血液樣本。Streck 血漿游離DNA采血管內含防腐劑，它能穩(wěn)定有核血細胞，防止細胞基因組DNA的釋放，保護血漿游離循環(huán)DNA和循環(huán)腫瘤細胞（CTC）。

230253是Streck Cell-Free DNA BCT® 10mL采血管218962的升級版，是Streck公司新推將玻璃和塑料的*性能融合在一起的Fusion2^TM混合塑料管。

Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管應用

NIPT無創(chuàng)產前檢測：孕婦外周血的胎兒游離DNA保存

腫瘤液體活檢：循環(huán)腫瘤細胞（CTCs）和ctDNA（循環(huán)腫瘤DNA）保存

其他：血漿基因組DNA和游離DNA保存

Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管基因保存性能

游離DNA、細胞內基因組DNA和循環(huán)腫瘤細胞樣本保存/穩(wěn)定性

血漿游離循環(huán)腫瘤DNA（ctDNA）保存管

Streck 218962（現(xiàn)貨）,230253 Cell-Free DNA BCT采血管及更多液體活檢產品歡迎您咨詢華雅再生醫(yī)學旗艦公司：紅榮微再（上海）生物工程技術有限公司  ：1500 1904 520。紅榮微再-客服: 2395557778  經銷商專員。紅榮微再以“傳遞科學價值，服務科學研究”為宗旨，主營干細胞、醫(yī)療、細胞治療、器官再生四大板塊的產品。

血漿游離循環(huán)腫瘤DNA（ctDNA）保存管

Streck BCT采血管的Circulating Tumor DNA (ctDNA)保存文獻

Development and clinical utility of a blood-based test service for the rapid identification of actionable mutations in non-small cell lung carcinoma

Mellert H., Foreman T., Jackson L, Maar D., Thurston S., Koch K. et al.

The Journal of Molecular Diagnostics, May 2017.

Application of circulating tumor DNA in prospective clinical oncology trials –standardization of preanalytical conditions

van Dessel L.F., Beije N., Helmijr J.C., Vitale S.R., Kraan J., Look M.P., et al.

Molecular Oncology, 2017.

Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: comparison to ctDNA and tissue in metastatic colorectal cancer

Kidess-Sigal E., Liu H.E., Triboulet M.M., Che J, Ramani V.C., Visser B.C., et al.

Oncotarget November, 2016.

Performance of Streck cfDNA blood collection tubes for liquid biopsy testing

Diaz I.M., Nocon A., Mehnert D.H., Fredebohm J., Diehl F.,Holtrup F.

PLoS One, 2016

Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer

Sacher A.G., Paweletz C., Dahlberg S., Alden R., O’Connell A., Feeney N., et al.

Journal of the American Medical Association Oncology, 2016.

Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next generation sequencing of cell-free circulating tumor DNA

Thompson J.C., Yee S.S., Troxel A.B., Savitch S.L., Fan R., Balli D., et al.

Clinical Cancer Research, 2016.

Optimized pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC)

Sherwood J.L., Corcoran C., Brown H., Sharpe A.D., Musilova M.,Kohlman A.

PLoS One, 2016.

ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients

Chu D., Paoletti C., Gersch C., VanDenBerg D.A., Zabransky D.J., Cochran R.L., et al.

Clinical Cancer Research, 2016.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

Schiavon G., Hrebien S., Garcia-Murillas I., Cutts R.J., Pearson A., Tarazona N., et al.

Science Translational Medicine, 2015.

Analytical and clinical validation of a digital Measurement of circulating cell-free DNA in sequencing panel for quantitative, highly accurate relation to 18F-fluorocholine PET/CT imaging in evaluation of cell-free circulating tumor DNA chemotherapy-treated advanced prostate cancer

Lanman R.B., Mortimer S.A., Zill O.A., Sebisanovic D., Kwee S., Song M.A., Cheng I., Loo L., Tiirikainen M.,Lopez R., Blau S., et al. Clinical & Translational Science, 2012.

PLoS One, 2015.

Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas

Zill O.A., Greene C., Sebisanovic D., Siew L., Leng J., Vu M., et al. Cancer Discovery, 2015.

Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA

Toro P.V., Erlanger B., Beaver J.A., Cochran R.L., VanDenBerg D.A., Yakim E., et al.

Clinical Biochemistry, 2015.

Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology

Kirkizlar E., Zimmermann B., Constantin T., Swernerton R., Hoang B., Wayham N., et al.

Translational Oncology, 2015.

Efficient detection of BRAF mutation in plasma of patients after long-term storage of blood in cell?free DNA blood collection tubes

Denis M.G., Knol A.C., Theoleyre S., Vallee A., Dreno B. Clinical Chemistry, 2015.

Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin’s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study

Vandenberghe P., Wlodarska I., Tousseyn T., Dehaspe L., Dierickx D., Verheecke M., et al.

The Lancet, 2015.

Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform

Kidess E., Heirich K., Wiggin M., Vysotskaia V., Visser B.C., Marziali A., et al.

Oncotarget, 2014.

血漿游離循環(huán)腫瘤DNA（ctDNA）保存管

——Streck Cell-Free DNA BCT® 血漿游離DNA采血/保存管

訂購信息

血漿游離循環(huán)腫瘤DNA（ctDNA）保存管

Streck 218962（現(xiàn)貨）,230253 Cell-Free DNA BCT采血管及更多液體活檢產品歡迎您咨詢華雅再生醫(yī)學旗艦公司：紅榮微再（上海）生物工程技術有限公司  ：1500 1904 520。紅榮微再-客服: 2395557778  經銷商專員。紅榮微再以“傳遞科學價值，服務科學研究”為宗旨，主營干細胞、醫(yī)療、細胞治療、器官再生四大板塊的產品。